<2> Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224
<3> Krystal Biotech Inc. (KRYS) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare dermatological and genetic disorders. The company’s lead product candidate, KB105, is currently in Phase 2 clinical trials for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic disorder that affects the skin and mucous membranes.
<4> In a recent note, Guggenheim analyst, Yatin Suneja, upgraded his price target on Krystal Biotech to $284 from $224, citing the company’s promising pipeline and the potential for KB105 to become a best-in-class treatment for DEB. Suneja also noted that Krystal Biotech’s focus on rare diseases positions the company for long-term growth and potential partnerships with larger pharmaceutical companies.
<5> Krystal Biotech’s pipeline also includes KB103, a topical gel formulation of KB105, which is currently in Phase 1 clinical trials for the treatment of DEB. The company’s pipeline also includes several preclinical programs, including KB104, a gene therapy candidate for the treatment